SECURITIES AND EXCHANGE COMMISSION
                       Washington, D.C. 10549
                             FORM 10-QSB



(Mark One)

[x]  Quarterly report under Section 13 or 15(D) of the Securities
     Exchange Act of 1934

            For the quarterly period ended June 30, 2000

[ ]  Transition report under Section 13 or 15(D) of the Exchange Act


     For the transition period from ____________ to ____________


                   Commission file number 0-15888


                      IGENE Biotechnology, Inc.
     _______________________________________________________________
    (Exact name of Small Business Issuer as Specified in its Charter)


             Maryland                           52-1230461
 _______________________________    ____________________________________
 (State or Other Jurisdiction of    (I.R.S. Employer Identification No.)
  Incorporation or organization)


         9110 Red Branch Road, Columbia, Maryland 21045-2024
         ___________________________________________________
              (Address of Principal Executive Offices)


                           (410) 997-2599
          ________________________________________________
          (Issuer's Telephone Number, Including Area Code)


                                None
        ____________________________________________________
        (Former Name, Former Address and Former Fiscal Year,
                    if Changed Since Last Report)



Check whether the Issuer: (1) filed all reports required to be filed
by Section 13 or 15(D) of the Exchange Act during the past 12 months
(or for such shorter period that the registrant was required to file
such reports), and (2) has been subject to such filing requirements
for the past 90 days.

Yes       x              No


State the number of shares outstanding of each of the issuer's
classes of common equity, as of the latest practicable date:
59,708,881 as of July 31, 2000.

Transitional Small Business Disclosure Format (check one):

Yes                      No        x

                                 -1-

                             FORM 10-QSB
              IGENE Biotechnology, Inc. and Subsidiary


                                INDEX


PART I    -    FINANCIAL INFORMATION
                                                              Page

          Consolidated Balance Sheets                          5-6

          Consolidated Statements of Operations                  7

          Consolidated Statements of Stockholder's Deficit     8-9

          Consolidated Statements of Cash Flows              10-11

          Notes to Consolidated Financial Statements         12-15

          Management's Discussion and Analysis of Financial
          Condition and Results of Operations                16-20

PART II   -    OTHER INFORMATION                             21-22

SIGNATURES                                                      23

                                 -2-

              IGENE BIOTECHNOLOGY, INC. AND SUBSIDIARY

             QUARTERLY REPORT UNDER SECTION 13 OR 15(D)

               OF THE SECURITIES EXCHANGE ACT OF 1934

                                 -3-

                               PART I

                        FINANCIAL INFORMATION

                                 -4-
Item 1.  Financial Statements.
<TABLE>
            IGENE Biotechnology, Inc. and Subsidiary
                   Consolidated Balance Sheets

<CAPTION>
                                               June 30,     June 30,  December 31,
                                                   2000         1999          1999
                                            ------------ ------------ ------------
                                            (Unaudited)  (Unaudited)
<S>                                         <C>          <C>          <C>
ASSETS

CURRENT ASSETS

  Cash and cash equivalents                 $   100,099  $    63,185  $     6,297
  Accounts receivable                            96,036        8,955       24,267
  Inventory                                     627,180      990,320      707,595
  Loan receivable, current portion                  ---      206,780      206,780
  Prepaid expenses and other current assets     204,004      223,482      153,160
                                            ------------ ------------ ------------
     TOTAL CURRENT ASSETS                     1,027,319    1,492,722    1,308,099


OTHER ASSETS
  Property and equipment, net                   131,825      356,404      366,484
  Deferred Costs, net                           541,217      158,784      137,613
  Other assets                                    4,876        4,875        4,876
                                            ------------ ------------ ------------
     TOTAL ASSETS                           $ 1,705,237  $ 2,012,785  $ 1,817,072
                                            ============ ============ ============
</TABLE>

The accompanying notes are an integral part of the consolidated
financial statements.

                               -5-

            IGENE Biotechnology, Inc. and Subsidiary
                   Consolidated Balance Sheets
                           (continued)

<TABLE>
                                                June 30,     June 30, December 31,
                                                    2000         1999         1999
                                            ------------ ------------ ------------
                                            (Unaudited)  (Unaudited)
<S>                                         <C>          <C>          <C>
LIABILITIES, REDEEMABLE PREFERRED STOCK
  AND STOCKHOLDERS' DEFICIT

CURRENT LIABILITIES
  Accounts payable and accrued expenses     $   294,268  $   231,971  $   268,081
LONG-TERM DEBT
  Promissory notes payable                    6,077,300    6,158,199    6,082,500
  Variable rate subordinated debenture        1,500,000    1,500,000    1,500,000
  Accrued Interest                            1,086,043      608,250      851,131
                                            ------------ ------------ ------------
     TOTAL LIABILITIES                        8,957,611    8,498,420    8,702,131
                                            ------------ ------------ ------------
COMMITMENTS AND CONTINGENCIES

REDEEMABLE PREFERRED STOCK
  Carrying amount of redeemable preferred
     stock, 8% cumulative, convertible,
     voting, series A, $.01 par value per
     share. Redemption value $15.52, $14.88,
     and $15.20, respectively.  Authorized
     1,312,500 shares, issued 26,467, 29,592,
     and 26,467 shares, respectively            410,768      440,329      402,298
                                            ------------ ------------ ------------
STOCKHOLDERS' DEFICIT
     Common stock, $.01 par value per share.
     Authorized, 250,000,000 shares;
     issued and outstanding 56,208,881,
     34,427,600, and 47,598,758 shares,
     respectively.                              562,089      344,275      475,988
  Additional paid-in capital                 20,789,533   19,442,586   20,238,904
  Deficit                                   (29,014,764) (26,712,825) (28,002,249)
                                            ------------ ------------ ------------

     TOTAL STOCKHOLDERS' DEFICIT             (7,663,142)  (6,925,964)  (7,287,357)
                                            ------------ ------------ ------------
     TOTAL LIABILITIES, REDEEMABLE
       PREFERRED STOCK AND
       STOCKHOLDERS' DEFICIT                $ 1,705,237  $ 2,012,785  $ 1,817,072
                                            ============ ============ ============
</TABLE>

The accompanying notes are an integral part of the consolidated
financial statements.

                               -6-

<TABLE>
            IGENE Biotechnology, Inc. and Subsidiary
              Consolidated Statements of Operations
                           (Unaudited)

<CAPTION>

                                              Three months ended         Six months ended
                                           ----------------------   --------------------------
                                             June 30,    June 30,       June 30,      June 30,
                                                 2000        1999           2000          1999
                                           ----------  ----------   ------------  ------------
<S>                                        <C>         <C>          <C>           <C>
Sales                                      $ 180,631   $     ---    $   259,167   $       ---
Cost of sales                                185,224      99,409        272,657       119,845
                                           ----------  ----------   ------------  ------------
  Gross profit (loss)                         (4,593)    (99,409)       (13,490)     (119,845)
                                           ----------  ----------   ------------  ------------
Selling, General & Administrative expenses:
  Marketing and selling                      179,457      46,475        258,598        52,925
  Research, development and pilot plant       84,967      90,101        177,576       190,400
  General and administrative                 125,233      80,902        210,102       170,546
  Litigation expenses                            850     182,757         11,896       358,494
                                           ----------  ----------   ------------  ------------
     Total operating expenses                390,507     400,235        658,172       772,365
                                           ----------  ----------   ------------  ------------
     Operating loss                         (395,100)   (499,644)      (671,662)     (892,210)
                                           ----------  ----------   ------------  ------------
Other income (expense)
  Interest expense, net of
     interest income of $3,544, $4,277,
     $3,646 and $10,948, respectively       (169,217)   (173,059)      (343,003)     (343,706)
  Other                                        2,150         ---          2,150           ---
                                           ----------  ----------   ------------  ------------
     Net loss                              $(562,167)  $(672,704)   $(1,012,515)  $(1,235,916)
                                           ==========  ==========   ============  ============
     Net loss per common share             $   (0.01)  $   (0.02)   $     (0.02)  $     (0.04)
                                           ==========  ==========   ============  ============

</TABLE>

The accompanying notes are an integral part of the consolidated
financial statements.

                               -7-
<TABLE>

            IGENE Biotechnology, Inc. and Subsidiary
        Consolidated Statements of Stockholders' Deficit
                           (Unaudited)


<CAPTION>

                                                      Redeemable Preferred Stock
                                                            (shares/amount)
                                                      ---------------------------
<S>                                                   <C>             <C>
Balance at December 31, 1998                             29,592       $ 430,860

Cumulative undeclared dividends
  on redeemable preferred stock                             ---           9,469

Issuance of common stock in lieu of
  cash in payment of interest on
  subordinated debenture                                    ---             ---

Issuance of common stock in lieu of
  cash in payment of legal fees                             ---             ---

Issuance of shares of common stock
  pursuant to direct purchases
  by certain directors and other
  accredited investors (note 3)                             ---             ---

Net loss for six months ended
  June 30, 1999                                             ---             ---
                                                      ----------      ----------
Balance at June 30, 1999                                 29,592       $ 440,329
                                                      ==========      ==========

Balance at December 31, 1999                             26,467       $ 402,298

Cumulative undeclared dividends
  on redeemable preferred stock                             ---           8,470

Exercise of employee stock options                          ---             ---

Exercise of warrants                                        ---             ---

Issuance of common stock in lieu of
  cash in payment of interest on
  subordinated debenture                                    ---             ---

Issuance of common stock pursuant to
  Direct purchases by certain directors                     ---             ---

Net loss for six months
  ended June 30, 2000                                       ---             ---
                                                      ----------      ----------
Balance at June 30, 2000                                 26,467         410,768
                                                      ==========      ==========

</TABLE>

The accompanying notes are an integral part of the consolidated
financial statements.

                               -8-
<TABLE>

            IGENE Biotechnology, Inc. and Subsidiary
        Consolidated Statements of Stockholders' Deficit
                     (Unaudited - Continued)

<CAPTION>
                                                             Additional                  Total
                                          Common Stock       Paid-in                     Stockholders'
                                         (shares/amount)     Capital      Deficit        Deficit
                                      ---------------------  -----------  -------------  -------------
<S>                                   <C>         <C>        <C>          <C>            <C>
Balance at December 31, 1998          21,854,173  $ 218,542  $18,738,038  $(25,476,909)  $(6,520,329)

Cumulative undeclared dividends
  on redeemable preferred stock              ---        ---       (9,469)          ---        (9,469)

Issuance of common stock in lieu of
   cash in payment of interest on
   subordinated debenture                 40,000        400       89,600           ---        90,000

Issuance of common stock in lieu of
  cash in payment of legal fees          866,667      8,666       41,084           ---        49,750

Issuance of shares of common stock
  pursuant to direct purchases
  by certain directors and other
  accredited investors (note 3)       11,666,760    116,668      583,332           ---       700,000

Net loss for six months ended
  June 30, 1999                              ---        ---          ---    (1,235,916)   (1,235,916)
                                      ----------  ---------  -----------  -------------  ------------
Balance at June 30, 1999              34,427,600  $ 344,276  $19,442,585  $(26,712,825)  $(6,925,964)
                                      ==========  =========  ===========  =============  ============
Balance at December 31, 1999          47,598,758  $ 475,988  $20,238,904  $(28,002,249)  $(7,287,357)

Cumulative undeclared dividends
   on redeemable preferred stock             ---        ---       (8,470)          ---        (8,470)

Exercise of employee stock options     1,500,000     15,000      135,000           ---       150,000

Exercise of warrants                   3,070,123     30,701      (25,501)          ---         5,200

Issuance of common stock in lieu of
   cash in payment of interest on
   subordinated debenture                 40,000        400       89,600           ---        90,000

Issuance of common stock pursuant
   to direct purchases by
   certain directors                   4,000,000     40,000      360,000           ---       400,000

Net loss for six months ended
   June 30, 2000                             ---        ---          ---    (1,012,515)   (1,012,515)
                                      ----------  ---------  -----------  -------------  ------------
Balance at June 30, 2000              56,208,881  $ 562,089  $20,789,533  $(29,014,764)  $(7,663,142)
                                      ==========  =========  ===========  =============  ============
</TABLE>

The accompanying notes are an integral part of the consolidated
financial statements.

                               -9-
<TABLE>

            IGENE Biotechnology, Inc. and Subsidiary
              Consolidated Statements of Cash Flows
                           (Unaudited)



<CAPTION>
                                                                  Six months ended
                                                              June 30,        June 30,
                                                                  2000            1999
                                                            ------------   ------------
<S>                                                         <C>            <C>
Cash flows from operating activities:
   Net loss                                                 $(1,012,515)   $(1,235,916)
   Adjustments to reconcile net loss to net cash used
     by operating activities:
     Depreciation                                                 9,624         41,600
     Amortization                                                29,186         21,172
     Interest on debenture paid in shares of common stock        90,000         90,000
     Decrease (increase) in:
       Accounts receivable                                     (353,031)        (8,955)
       Inventory                                                 79,073       (120,060)
       Prepaid expenses and other current assets                (52,186)      (108,404)
     Increase (decrease) in:
       Accounts payable and accrued expenses                    544,627        231,472
                                                            ------------   ------------
       Net cash used in operating activities                   (665,222)    (1,089,091)
                                                            ------------   ------------
Cash flows from investing activities:
   Proceeds from disposal of equipment                              ---            460
   Capital expenditures                                            (976)       (28,407)
   Refund of security deposit                                       ---          5,725
   Repayment of principal of loan receivable                        ---         44,003
                                                            ------------   ------------
       Net cash provided by (used in) investing activities         (976)        21,781
                                                            ------------   ------------
Cash flows from financing activities:
   Proceeds from issuance of common stock                       550,000        700,000
   Issuance of promissory notes                                     ---         65,699
                                                            ------------   ------------
       Net cash provided by financing activities                550,000        765,699
                                                            ------------   ------------
       Net decrease in cash
         and cash equivalents                                  (116,198)      (301,611)

       Cash and cash equivalents
         at beginning of period                                 216,297        364,796
                                                            ------------   ------------
       Cash and cash equivalents
          at end of period                                  $   100,099    $    63,185
                                                            ============   ============
</TABLE>

The accompanying notes are an integral part of the consolidated
financial statements.

                              -10-

            IGENE Biotechnology, Inc. and Subsidiary
              Consolidated Statements of Cash Flows
                     (Unaudited - Continued)

Noncash investing and financing activities:

During  the  six months ended June 30, 2000 and 1999, the Company
recorded dividends in arrears on 8% redeemable preferred stock at
$.32  per  share  aggregating $ 8,470 and  $9,469,  respectively,
which  has been removed from paid-in capital and included in  the
carrying value of the redeemable preferred stock.

During  the  six months ended June 30, 2000 and 1999 the  Company
issued 40,000 shares of common stock in each period in payment of
interest on the variable rate subordinated debenture.  If paid in
cash,  the interest would have been payable at 12% in the  amount
of  $90,000 in each period.  Shares may be issued in lieu of cash
under the terms of the debenture agreement at the higher of $2.25
per  share  or market price per share.  The stock was issued  and
related interest was paid at $2.25 per share, or $90,000, in each
period.

During the six months ended  June 30,  2000,  Igene agreed to the
repayment  of  $206,780  in  loans  receivable  and  the  sale of
equipment  having  a  net  book  value  of  $226,011 as part of a
reduction  in  manufacturing   fees  under  a  new contract  with
the Company's contract manufacturer of AstaXin(R). The book value
of the loan receivable and equipment, totaling $432,791, has been
recorded  as  a  deferred  cost  which  is  being  amortized   as
manufacturing  occurs  over  the  six year term of this contract,
which will expire May 2006.

During  the six months ended June 30, 2000, holders of  3,994,500
warrants issued in the March 1998 Rights Offering exercised those
warrants  using  $5,200 of notes payable to Igene  and  utilizing
927,377  warrants  in cashless exercises.  3,070,123  new  shares
were  issued and $5,200 of notes payable were cancelled in  these
transactions.

During  the six months ended June 30, 1999, the Company satisfied
accounts  payable  of  $20,000 and  advanced  $29,750  for  legal
retainers by issuing 866,667 shares of common stock to counsel in
on-going litigation.




The accompanying notes are an integral part of the consolidated
financial statements.

                              -11-

            IGENE Biotechnology, Inc. and Subsidiary
           Notes to Consolidated Financial Statements


(1)  Basis of Presentation

     The   consolidated  interim  financial  statements  included
     herein  have  been prepared by the Company,  without  audit,
     pursuant to the rules and regulations of the Securities  and
     Exchange   Commission.  Certain  information  and   footnote
     disclosures   normally  included  in  financial   statements
     prepared  in  accordance with generally accepted  accounting
     principles  have  been omitted pursuant to  such  rules  and
     regulations,   although  the  Company  believes   that   the
     disclosures  are adequate to make the information  presented
     not misleading.

     These  statements  reflect  all adjustments,  consisting  of
     normal  recurring  adjustments  which,  in  the  opinion  of
     management,  are  necessary for  fair  presentation  of  the
     information contained therein.  It is suggested  that  these
     consolidated  financial statements be  read  in  conjunction
     with the financial statements and notes thereto included  in
     the  Company's  annual report on form 10-KSB  for  the  year
     ended  December  31,  1999.  The Company  follows  the  same
     accounting  policies  in  preparation  of  interim  reports,
     except  as  described  in   note  (2)  to  the  consolidated
     financial statements.

(2)  Summary of Significant Accounting Policies

     Principles of Consolidation

     During   June   2000  the  Company  formed  a   wholly-owned
     subsidiary   in   Chile.    These   consolidated   financial
     statements  include the accounts of the Company and  of  its
     wholly-owned   subsidiary.   All  significant   intercompany
     accounts   and   transactions  have   been   eliminated   in
     consolidation.

     Deferred Costs

     Deferred  costs  include  deferred  manufacturing  costs  of
     $418,765,  which  represents the value, reduced  by  current
     amortization,   of  a  note  receivable  of   $206,780   and
     manufacturing equipment with a net book value  of  $226,011.
     These assets have been cancelled and sold, respectively,  in
     consideration for a reduction in manufacturing fees over the
     six  year term of a new manufacturing contract which  became
     effective  in May 2000.  These deferred manufacturing  costs
     are  being amortized over the term of the contract, and such
     amortization,  in the amount of $14,026 for the  six  months
     ended June 30, 2000, is included in Cost of  Sales.

     Foreign Currency Translation and Transactions

     Since  the  day-to-day operations of the  Company's  foreign
     subsidiary   in   Chile  are  dependent  on   the   economic
     environment of the parent's currency, the financial position
     and   results   of  operations  of  the  Company's   foreign
     subsidiary  are  determined using  the  Company's  reporting
     currency  (US  dollars) as the functional  currency.     All
     exchange  gains  and losses from remeasurement  of  monetary
     assets  and  liabilities  that are  not  denominated  in  US
     dollars are recognized currently in income.  These gains and
     losses were immaterial in amount during the six months ended
     June 30, 2000.

     Statements of Cash Flows

     The  Company  has  determined that  the  effect  of  foreign
     exchange rate changes on cash flows is not material.

                              -12-

            IGENE Biotechnology, Inc. and Subsidiary
           Notes to Consolidated Financial Statements
                           (continued)

(3)  Inventories

     Inventory, stated at lower of cost, on a first-in  first-out
     basis, or market value, represents AstaXin(R) manufactured and
     held for sale, as follows:

          Raw materials            $         ---
          Work-in-process                    ---
          Finished goods                 627,180
                                   --------------
               Total inventory     $     627,180
                                   ==============

(4)  Stockholders' Deficit

     At  June 30, 2000 and 1999, 52,934 shares of authorized  but
     unissued   common  stock  were  reserved  for   issue   upon
     conversion of the Company's outstanding preferred stock.

     As  of  June  30,  2000 and 1999, 19,910,166 and  21,410,166
     shares,  respectively,  of authorized  but  unissued  common
     stock  were reserved for exercise pursuant to the  Company's
     Employee Stock Option Plans.

     As  of  June 30, 2000 and 1999, 200,000 and 280,000  shares,
     respectively, of authorized but unissued common  stock  were
     reserved  for  issuance  for  payment  of  interest  on  the
     variable  rate subordinated debenture and 375,000 shares  of
     authorized  but  unissued  common stock  were  reserved  for
     issuance  upon conversion of the variable rate  subordinated
     debenture.

     As   of  June  30,  2000  and  1999,  13,174,478  shares  of
     authorized but unissued common stock were reserved  for  the
     conversion  of outstanding convertible promissory  notes  in
     the  aggregate amount of $1,082,000 held by directors of the
     Company.

     As  of  June  30, 2000 and 1999, 131,759,345 and 113,462,178
     shares,  respectively,  of authorized  but  unissued  common
     stock   were   reserved  for  the  exercise  of  outstanding
     warrants.

     As  of  June  30,  2000, 6,000,000 shares of authorized  but
     unissued  shares of common stock were reserved for  issuance
     upon  receipt of $600,000 in funding for operations pursuant
     to  a  $1,000,000  commitment by certain  directors  of  the
     Company on February 8, 2000.

     As  of  June  30, 2000, 20,000,000 shares of authorized  but
     unissued  shares of common stock were reserved for  issuance
     pursuant to the production of AstaXin(R)in an agreement with
     Igene's contract manufacturer.

     During the  six  months  ended  June  30,  2000, the Company
     issued  to  certain directors 4,000,000 new shares of common
     stock at $.10 per share,  or $400,000  (the Company incurred
     no offering expenses).  The Company did not use the services
     of any  agent or  underwriter  in distributing these shares.
     The sale  of shares was exempt from registration pursuant to
     Section 4(2) of the Securities Act.    The Company relied on
     information  provided  by  the  purchasers  of  the  shares,
     indicating  that  they  were  directors  of  the Company, in
     claiming  exemption from the registration obligations of the
     Securities  Act  of 1933, as amended.  This stock was issued
     pursuant to a  commitment dated February 8, 2000 for a total
     of  $1,000,000.   The market price on that date was $.10 per
     share.   In return for this commitment, these directors also
     received,  on   February  8,  2000,  warrants   to  purchase
     10,000,000  shares  of  common  stock  at  $0.10  per share,
     expiring in 10 years.

     During  the  six  months ended June 30,  2000,  the  Company
     issued  1,500,00  new shares of common  stock  at  $.10  per
     share,  or  $150,000, pursuant to the exercise  of  employee
     stock options.

                              -13-

            IGENE Biotechnology, Inc. and Subsidiary
           Notes to Consolidated Financial Statements
                           (continued)


(4)  Stockholders' Deficit (continued)

     During  the  six  months ended June  30,  2000,  holders  of
     3,994,500 warrants issued in the March 1998 Rights  Offering
     exercised  those warrants using $5,200 of notes  payable  to
     Igene  and utilizing 927,377 warrants in cashless exercises.
     3,070,123 new shares were issued and $5,200 of notes payable
     were cancelled in these transactions.

     On  January 25, 1999 the Company issued to certain directors
     and  other  accredited  investors 4,166,667  new  shares  of
     common  stock at $.06 per share, or $250,000, which was  the
     current  market  price of the stock  on  that  date.   These
     investors also committed to purchase an additional 8,333,333
     new shares of common stock at $.06 per share, or $500,000 by
     July  31,  1999.  The total funding to be received  in  this
     transaction  is  $750,000, and a total of 12,500,000  shares
     will  be issued at $.06 per share.  In return for committing
     to  this  funding,  these investors  also  received,  as  of
     January 25, 1999, warrants to purchase 12,500,000 shares  of
     common stock at $.06 per share, expiring in 10 years.  As of
     June  30,  1999, $700,000 of the committed funding has  been
     received  from  investors and 11,666,667  shares  have  been
     issued at $.06 per share.

(5)  Net loss per common share

     Net  loss per common share for the three month periods ended
     June   30,  2000  and  1999  is  based  on  53,899,650   and
     30,132,254, respectively, of weighted average common  shares
     outstanding.   Net loss per common share for  the  six-month
     periods ended June 30, 2000, and 1999 is based on 51,323,947
     and  27,751,637,  respectively, of weighted  average  common
     shares  outstanding. For purposes of computing net loss  per
     common  share, the amount of net loss has been increased  by
     cumulative  undeclared  dividends in  arrears  on  preferred
     stock.

(6)  Commitments

     On   May  20,  2000  the  Company  signed  a  Memorandum  of
     Understanding whereby it renewed its manufacturing agreement
     with  Fermic, S.A. de C.V. (Fermic) of Mexico City,  Mexico.
     Production  began under this Memorandum  on  May  20,   2000
     while a detailed contract is being drafted.  The major terms
     of  the  agreement provide for the exclusive manufacture  of
     AstaXin(R) by Fermic during a six year term.  Fermic will be
     paid  a monthly fee based on manufacturing capacity provided
     and will also be issued shares of Igene's common stock based
     on the  amount of AstaXin(R) produced, up to  a  maximum  of
     20,000,000 shares over the term of the contract.

(7)  Contingencies

     On  July 21, 1997, ADM filed suit against the Company in the
     U.S.  District Court in Baltimore, Maryland alleging  patent
     infringement  and  requesting  injunctive  relief   and   an
     unspecified  amount  of damages predicated  on  the  alleged
     infringement,  which alleged infringement  pertains  to  the
     Company's  astaxanthin manufacturing process.  On August  4,
     1997,  the  Company filed a $300,450,000 contract and  trade
     secrets  counterclaim against ADM, alleging theft  of  trade
     secrets.   The Company is also claiming breach of  contract,
     in  regards  to a licensing agreement entered  into  by  the
     Company  and  ADM  in 1995.  The Company  contends  that  it
     complied  with  all  material terms of this  agreement.   On
     September  10, 1997 the District Court denied ADM's  request
     for a preliminary injunction on the basis that ADM could not
     demonstrate  a  likelihood of success on the merits  of  its
     patent  infringement allegations.  To date, a  stay  on  all
     discovery  has  been imposed by the court,  while  a  court-
     appointed  expert  analyzes  the  yeast  products  of   both
     parties.  Pursuant to an order issued by the judge  on  July
     16,  1999, both the Company and ADM have communicated to the
     court  their willingness to pursue a mediated settlement  of
     this dispute.

                              -14-

            IGENE Biotechnology, Inc. and Subsidiary
           Notes to Consolidated Financial Statements
                           (continued)


(7)  Contingencies (continued)

     During  the period from October 1, 1999 through October  28,
     1999, the parties were unable to resolve the dispute through
     mediation.   Thus, the litigation has been returned  to  the
     court  for  a  judicial  disposition.   It  is  management's
     contention  that it is not probable that this  dispute  will
     result in an unfavorable outcome.  Accordingly, no liability
     has  been reflected in the accompanying consolidated balance
     sheets.   The  Company  had expenses of  $850  and  $182,757
     respectively, in the six months ended June 30, 2000 and 1999
     relating to this litigation, which is on-going.

(8)  Subsequent Events

     On  July  17,  2000,  the  Company received  $350,000  in  a
     purchase  of  new  stock by certain directors  of  3,500,000
     shares of common stock at $0.10 per share.  This transaction
     was  the  third in a planned series of purchases  of  common
     stock  pursuant  to a commitment, on February  8,  2000,  to
     purchase stock in the total amount of $1,000,000.

     In  a  notice published in the Federal Register of  July  6,
     2000,  the FDA announced the amendment of its color additive
     regulations  to  provide for the safe use of phaffia  yeast,
     such  as  that in  the  Company's  product, AstaXin(R), as a
     color additive in aquaculture feeds.  This ruling, which  is
     effective  August 8, 2000, allows the Company to market  its
     product, AstaXin(R), for aquaculture feeds and fish produced
     in or imported into the United States.

     In  July  2000,  the Company also obtained market  clearance
     from  the FDA  to sell its product, AstaXin(R), as  a  human
     nutritional  supplement  in the United  States.   Scientific
     literature indicates that natural astaxanthin, such as  that
     in  the  Company's  product, AstaXin(R),  may  offer  health
     benefits for humans due to its antioxidant properties.


                              -15-

            IGENE Biotechnology, Inc. and Subsidiary
             Management's Discussion and Analysis of
          Financial Condition and Results of Operations



CAUTIONARY STATEMENT FOR PURPOSES OF "SAFE HARBOR PROVISIONS"  OF
THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995:

EXCEPT  FOR  HISTORICAL  FACTS, ALL  MATTERS  DISCUSSED  IN  THIS
REPORT, WHICH ARE FORWARD LOOKING, INVOLVE A HIGH DEGREE OF RISKS
AND  UNCERTAINTIES.   POTENTIAL RISKS AND UNCERTAINTIES  INCLUDE,
BUT   ARE  NOT  LIMITED  TO,  COMPETITIVE  PRESSURES  FROM  OTHER
COMPANIES AND WITHIN THE BIOTECH INDUSTRY, ECONOMIC CONDITIONS IN
THE  COMPANY'S  PRIMARY MARKETS AND OTHER UNCERTAINTIES  DETAILED
FROM  TIME-TO-TIME  IN  THE  COMPANY'S  SECURITIES  AND  EXCHANGE
COMMISSION FILINGS.

Certain   statements  in  this  report  set  forth   management's
intentions,  plans, beliefs, expectations or predictions  of  the
future  based on current facts and analyses.  Actual results  may
differ materially from those indicated in such statements, due to
a  variety of factors including reduced product demand, increased
competition,  government action, weather  conditions,  and  other
factors.

Overview

Igene  Biotechnology, Inc. (Igene) is engaged in the business  of
developing,  marketing, and manufacturing industrial microbiology
and  related  biotechnology products.  Igene's major  product  is
AstaXin(R),  a dried yeast product made from a proprietary strain
of  yeast which it has developed.  AstaXin(R) is a natural source
of astaxanthin, the pigment which imparts the characteristic  red
color  to the flesh of salmon, shrimp and certain other types  of
fish  and  shellfish.   In the ocean, these  fish  and  shellfish
obtain astaxanthin from krill and other planktonic crustaceans in
their diet.   However, without the addition of astaxanthin to the
feed  of farm raised fish and shellfish, their flesh would  be  a
pale,  off-white  color,  which is less appealing  to  consumers.
Based on estimates of worldwide production of farm raised salmon,
Igene  believes  that the worldwide market for astaxanthin  as  a
feed  additive  for  aquaculture exceeds  $200,000,000  annually.
Scientific  literature also indicates that  natural  astaxanthin,
such as that in AstaXin(R), may offer health benefits for  humans
due  to its antioxidant properties, which exceed those of vitamin
E,  vitamin C, beta-carotene and other carotenoids.  The  Company
is presently manufacturing, marketing and selling AstaXin(R) as a
color  additive for aquaculture feeds, and is also  preparing  to
market this product as a human nutritional supplement.

Results of Operations

On July 6, 2000, a U.S. FDA ruling, which was effective August 8,
2000, allowed Igene to market AstaXin(R) for fish feeds and  fish
produced  in or sent to the United States.  As a result  of  this
U.S.  FDA  ruling,  and  approvals  in  1999  from  the  Canadian
equivalent agency, Igene began to market AstaXin(R) in the United
States  and  Canada  in  July 2000.  In  July  2000,  Igene  also
obtained market clearance from the U.S. FDA to sell AstaXin(R) as
a human nutritional supplement in the United States.

Sales

Sales of AstaXin(R) for aquaculture feed were $180,631 during the
quarter  ended June 30, 2000.  This is an increase of  130%  over
sales for  the preceding quarter of $78,536.  Sales of AstaXin(R)
for  the six months ended June 30, 2000 totaled $259,167.   Based
on   actual   sales  through  July  2000,  orders  received   and
projections  of the usage for current customers,  sales  for  the
quarter ended September 30, 2000 are expected to exceed $400,000.
During the three months and six months ended June 30, 1999  Igene
had no sales of AstaXin(R) while the Company conducted  what  was
probably the largest commercial fish feeding study in the  world,
using  AstaXin(R) in  Chile in cooperation with more than a dozen
fish  producers.    Results  obtained  from  this  study  and  an
independent  study  conducted in Norway by Akvaforsk confirm that
natural  AstaXin(R)  is  comparable,  if  not  superior  to,  its
competitor'  synthetic  product  which  currently  dominates  the

                             -16-

            IGENE Biotechnology, Inc. and Subsidiary
             Management's Discussion and Analysis of
          Financial Condition and Results of Operations
                           (continued)


Results of Operations (continued)

market.  The  Akvaforsk  study  also  confirmed  the stability of
AstaXin(R) through the commercial  feed production   process  and
showed  the  efficiency  of Igene's proprietary enzyme technology
for  making  98% of the astaxanthin  available  for uptake by the
fish  and  more  than  twice as effective as  other  competitors'
processes. Igene believes that sales of AstaXin(R)for aquaculture
will continue to grow, due to  both increased  sales in Chile and
marketing in the United States and Canada.  However, there can be
no  assurance  that such  sales  will occur or  that they will be
material.

Now  that U.S. FDA market clearance has been obtained, Igene also
plans to market  AstaXin(R)  as a human  nutritional  supplement.
Scientific literature indicates that natural astaxanthin, such as
from AstaXin(R), may offer certain health benefits for humans due
to  its antioxidant properties, which exceed those of vitamin  E,
vitamin C, beta-carotene and other carotenoids.

Cost of Sales

Igene resumed commercial production of AstaXin(R) in May 2000 and
entered  into  a six year exclusive agreement with  its  contract
manufacturer  in Mexico City, Mexico.  Igene is  now  capable  of
tripling its  production  capacity  for  AstaXin(R) within  three
months,  and to nine fold within a year, if necessary.   Cost  of
sales for AstaXin(R) for the quarter ended June 30, 2000 and 1999
of  $185,224 and $99,409 increased by $85,815, or 86%.   Cost  of
sales  of  AstaXin(R)  for the six months ended June 30, 2000 and
1999  of  $272,657  and  $119,845 increased by $152,812, or 128%.
These  increases  resulted  from  increased sales of AstaXin(R)in
2000 offset  by  adjustments  to decrease AstaXin(R) inventory to
market  value  during  the six months ended June 30, 1999.  There
have been no additional  decreases  of   AstaXin(R) inventory  to
market  value during  the  six months ended June 30, 2000, due to
increases in  production efficiency.  Igene  expects  to  achieve
gross profits on sales of AstaXin(R) in the near future, as sales
levels  increase.   However,  there can be no assurance that such
gross  profits  will occur or that they will be  material.  Igene
expects  that  cost  of  sales  for  AstaXin(R)  will continue to
increase,  due to  sales increases, and  they  are expected to be
funded  by  product sales.  Igene  plans  to  expand   production
capacity as  needed  to  meet   increasing demand for AstaXin(R).
However, there can be  no assurance  that  demand  will, in fact,
increase  or  that  such increases will be material.

Marketing and Selling Expenses

Igene  has engaged a full-time consultant to obtain approval  and
market  AstaXin(R) in  Europe  as a feed additive for aquaculture
and also to market AstaXin(R) worldwide as  a  human  nutritional
supplement.  Igene's  executive  employees  continue  to   travel
extensively    to   support    the   two   full-time    technical
representatives  at  its Chilean subsidiary's  office.  Marketing
expenses for AstaXin(R) are expected to continue to  increase  as
Igene  markets  AstaXin(R)  in  the  United  States  and  Canada.
Marketing  and selling expenses for the three months  ended  June
30,  2000  and  1999 were $179,457 and $46,475, respectively,  an
increase  of  $132,982, or 286%.  Marketing and selling  expenses
for the six months ended June 30, 2000 and 1999 were $258,598 and
$52,925,  respectively, an increase of $205,673, or 389%.  Future
additional  marketing  expenses are  expected  to  be  funded  by
revenues  from product sales.  However, there can be no assurance
that such sales will occur, or that they will be material.


                              -17-

            IGENE Biotechnology, Inc. and Subsidiary
             Management's Discussion and Analysis of
          Financial Condition and Results of Operations
                           (continued)


Results of Operations (continued)

Research, Development and Pilot Plant Expenses

Research,  development  and pilot plant expenses  for  the  three
months  ended  June 30, 2000 and 1999 were $84,967  and  $90,101,
respectively, a decrease of $5,134, or 6%. Research,  development
and  pilot plant expenses for the six months ended June 30,  2000
and 1999 were $177,576 and $190,400, respectively, a decrease  of
$12,824,  or  7%.  These  expenses are expected  to  continue  at
approximately  $30,000  per month in support  of  increasing  the
efficiency  of  the  AstaXin(R)  manufacturing  process   through
experimentation   in  the  pilot  plant  and  through   improving
proprietary technology. These expenses are expected to be  funded
by  sales.   However, there can be no assurance that  such  sales
will occur, or that they will be material.

General and Administrative Expenses

General  and  administrative expenses for the three months  ended
June  30,  2000 and 1999 were $125,233 and $80,902, respectively,
an  increase  of  $44,331,  or 55%.  General  and  administrative
expenses  for  the six months ended June 30, 2000 and  1999  were
$210,102  and $170,546, respectively, an increase of $39,538,  or
23%.   These  increases resulted primarily from costs  associated
with the annual shareholder's meeting which was held in June 2000
(in  1999 this meeting was not held until the third quarter)  and
from  increased legal expenses relating to warrants exercised  in
2000.  General  and  administrative  expenses  are  expected   to
continue  at approximately $35,000  per month in the  near  term,
and are expected to be funded by sales. However, there can be  no
assurance  that  such  sales will occur, or  that  they  will  be
material.

Litigation Expenses

Litigation expenses for the three months ended June 30, 2000  and
1999  were  $850  and $182,757, a decrease of $181,907,  or  99%.
Litigation  expenses for the six months ended June 30,  2000  and
1999  were $11,896 and $358,494, a decrease of $346,598, or  97%.
These  amounts  represent  the expenses associated  with  Igene's
defense   of   the  suit  by  ADM  alleging  patent  infringement
pertaining  to  Igene's  astaxanthin  manufacturing  process  and
Igene's  counter-suit.   These expenses have  decreased  while  a
court  imposed stay on discovery remains in effect and  a  court-
appointed  expert  analyzes the yeast products of  both  parties.
These  expenses  are  expected  to  increase  when  and  if   the
litigation  moves to a courtroom phase.   Management  expects  to
recover   these   legal  expenses  through  damage   awards   and
preservation  of  the commercial product rights  associated  with
AstaXin(R).  However, there can be no assurance that the  Company
will  receive damage awards or that its rights will be preserved.
Igene's  expenditures for this litigation will continue based  on
management's continuing assessments of the potential costs versus
the   potential  benefits   of  its  litigation  efforts.   These
expenses  are  expected  to  be  funded  by  additional   capital
contributions  or loans from directors.  At the present  time,  a
range  of reasonably possible loss from the litigation cannot  be
estimated.

Net interest expense for the three months ended June 30, 2000 and
1999  was  $169,217  and $173,059, respectively,  a  decrease  of
$3,842,  or  2%.  Net interest expense for the six  months  ended
June 30, 2000 and 1999 was $343,003 and $343,706, respectively, a
decrease  of   $703  or less than 1%.   It is expected  that  net
interest  expense  will  decrease  if   note  holders  will   use
outstanding  notes  to exercise outstanding  warrants  issued  to
them,  when  and  if the Company achieves profitable  operations.
However,   there  can  be  no  assurance  that  such   profitable
operations will occur, or that they will be material or that  the
holders will in fact use their notes to exercise their warrants.


                              -18-

            IGENE Biotechnology, Inc. and Subsidiary
             Management's Discussion and Analysis of
          Financial Condition and Results of Operations
                           (continued)

Results of Operations (continued)

As  a result of the foregoing, the Company reported net losses of
$562,167 and $672,704, or $0.01 and $.02 per share for the  three
months  ended  June  30,  2000,  and  1999,  and  net  losses  of
$1,012,515  and  $1,235,916,  or  $0.02  and  $0.04  per   share,
respectively, for the six months ended June 30, 2000 and 1999.

The weighted average number of shares of common stock outstanding
increased  to 53,899,650 for the six months ended June  30,  2000
from  30,132,254 for the six months ended June  30,  1999.   This
increase of 23,767,396 weighted average shares is caused  by  the
issuance  of  80,000 shares of common stock in lieu  of  interest
payments  on  the  variable  rate  subordinated  debenture,   the
conversion  of 3,125 shares of preferred stock into 6,250  shares
of common stock, the issuance of 1,500,000 shares pursuant to the
exercise  of  employee stock options, the issuance  of  3,068,323
shares pursuant to the exercise of warrants, and the issuance  of
17,125,001  shares  to  directors and other  investors  for  cash
during the twelve month period ended June 30, 2000.

Financial Position

During  the six months ended June 30, 2000 and 1999 the following
materially affected the Company's financial position:

The Company capitalized inventory of $990,320 as of June 30, 1999
due  to  production.  During the six months ended June  30,  2000
inventory  decreased to $627,180 due to product sales, offset  by
production.

During  the  six  months ended June 30, 2000 accounts  receivable
increased to $96,036 due to current product sales.

The  Company  paid expense advances and retainers of $330,000  to
its  attorneys during the six months ended June 30,  1999,  which
have been capitalized and are included in prepaid expenses as  of
June 30, 2000 and 1999, as reduced by fees billed, and which  are
being   drawn   down  against  costs  associated  with   on-going
litigation against ADM.

During  the  six  months ended June 30, 2000, Igene agreed to the
repayment  of  $206,780  in  loans  receivable  and  the  sale of
equipment  having  a  net  book  value  of $226,011 as part of  a
reduction in manufacturing fees under  a  new contract  with  the
Company's contract manufacturer of AstaXin(R).  The book value of
the loan receivable  and  equipment, totaling  $432,791, has been
recorded  as  a  deferred   cost  which  is  being  amortized  as
manufacturing  occurs  over  the  six year term of this contract,
which will expire May 2006.

During  the  six  months ended June 30, 1999 the  Company  issued
11,666,667  new  shares of common stock to  directors  and  other
investors at $.06 per share, or $700,000.  During the six  months
ended  June 30, 2000 the Company issued 4,000,000 new  shares  to
certain directors at $.10 per share or $400,000.

During  the six months ended June 30, 1999 the Company  purchased
$28,407 of research and development and manufacturing equipment.

During  the six months ended June 30, 2000, holders of  3,994,500
warrants issued in the March 1998 Rights Offering exercised those
warrants  using  $5,200 of notes payable to Igene  and  utilizing
927,377  warrants  in cashless exercises.  3,070,123  new  shares
were  issued and $5,200 of notes payable were cancelled in  these
transactions.

                              -19-

            IGENE Biotechnology, Inc. and Subsidiary
             Management's Discussion and Analysis of
          Financial Condition and Results of Operations
                           (continued)


Financial Position (continued)

During  the  six  months ended June 30, 2000 the  Company  issued
1,500,000 new shares of common stock pursuant to the exercise  of
employee stock options at $.10 per share or $150,000.

In  December  of  1988,  the  Company suspended  payment  of  the
quarterly  dividend on its preferred stock.   Resumption  of  the
dividend  will  require  significant improvement  in  cash  flow.
Unpaid  dividends  cumulate for future payment  or  increase  the
liquidation  preference  or redemption  value  of  the  preferred
stock.   As of June 30, 2000 and 1999, total dividends in arrears
on  the  Company's  preferred stock was  $199,032  and  $203,593,
respectively,  which was included in the carrying  value  of  the
redeemable preferred stock.

Liquidity and Capital Resources

Historically,  the  Company has been funded primarily  by  equity
contributions and loans from stockholders.  As of June  30,  2000
and  1999,  the  Company  had working  capital  of  $733,051  and
$1,260,751, respectively.  Working capital decreased by  $527,700
during  the twelve month period ended June 30, 2000.  The Company
had  cash and cash equivalents of $100,099 and $63,185 as of June
30,  2000 and 1999, respectively.  In order to continue  to  fund
operations  in the near term, until profitable operations  occur,
the  Company  plans  to  obtain  additional  capitalization  from
directors and other investors.

Cash used by operations in the six months ended June 30, 2000 and
1999  amounted  to  $665,222 and $1,089,091, respectively.   This
decrease in cash used in operations of $423,869 resulted  from  a
temporary halt in production of AstaXin(R) and increased  product
sales and reduced litigation expenses during the six months ended
June 30, 2000.

Cash  provided  (used  by) by investing activities  for  the  six
months  ended  June  30,  2000 and 1999 amounted  to  $(976)  and
$21,781,  respectively.  The decrease of $22,757 in cash provided
by investing activities resulted primarily from a decrease in the
amount of principal repayments on loan receivable during the  six
months  ended June 30, 2000.  This loan was repaid  in  May  2000
through  a  reduction in fees in the Company's new  manufacturing
contract.

Cash  provided by financing activities for the six  months  ended
June  30,  2000  and  1999  amounted to  $550,000  and  $765,699,
respectively, a decrease of $215,699, resulting primarily from  a
decrease  in proceeds from issue of new common stock  during  the
six months ended June 30, 2000.


                              -20-

            IGENE Biotechnology, Inc. and Subsidiary
                             PART II
                        OTHER INFORMATION

Item 1.  Legal Proceedings

On  July 21, 1997, ADM filed suit against the Company in the U.S.
District   Court   in   Baltimore,   Maryland   alleging   patent
infringement and requesting injunctive relief and an  unspecified
amount  of damages predicated on the alleged infringement,  which
alleged   infringement  pertains  to  the  Company's  astaxanthin
manufacturing  process.  On August 4, 1997, the Company  filed  a
$300,450,000 contract and trade secrets counterclaim against ADM,
alleging  theft of trade secrets.  The Company is  also  claiming
breach  of contract, in regards to a licensing agreement  entered
into  by the Company and ADM in 1995.  The Company contends  that
it  complied  with  all  material terms of  this  agreement.   On
September 10, 1997 the District Court denied ADM's request for  a
preliminary   injunction  on  the  basis  that  ADM   could   not
demonstrate a likelihood of success on the merits of  its  patent
infringement  allegations.  To date, a stay on all discovery  has
been  imposed  by  the  court,  while  a  court-appointed  expert
analyzes  the  yeast products of both parties.   Pursuant  to  an
order issued by the judge on July 16, 1999, both the Company  and
ADM have communicated to the court their willingness to pursue  a
mediated  settlement  of this dispute.  During  the  period  from
October 1, 1999 through October 28, 1999, the parties were unable
to  resolve  the dispute through mediation.  Thus, the litigation
has been returned to the court for a judicial disposition.  It is
management's contention that it is not probable that this dispute
will result in an unfavorable outcome.  Accordingly, no liability
has  been  reflected  in  the accompanying  consolidated  balance
sheets.    The   Company  had  expenses  of  $850  and   $182,757
respectively,  in  the six months ended June 30,  2000  and  1999
relating to this litigation, which is on-going.

Item 2.  Changes in Securities and Use of Proceeds.

Dividends on Common Stock are currently prohibited because of the
preferential rights of holders of Preferred Stock.   The  Company
has  paid  no cash dividends on its Common Stock in the past  and
does  not  intend to declare or pay any dividends on  its  Common
stock in the foreseeable future.

During the six months  ended  June  30,  2000, the Company issued
to certain directors 4,000,000 new shares of common stock at $.10
per  share,  or  $400,000  (the  Company  incurred  no   offering
expenses).  The Company did not use the services of any  agent or
underwriter  in distributing these shares. The sale of shares was
exempt  from  registration  pursuant  to  Section  4(2)  of   the
Securities Act. The Company relied on information provided by the
purchasers of the shares, indicating  that  they  were  directors
of the  Company, in  claiming  exemption  from  the  registration
obligations of the Securities Act of 1933, as amended. This stock
was issued pursuant to a  commitment dated February 8, 2000 for a
total of $1,000,000.   The market price on that date was $.10 per
share.   In  return  for  this  commitment,  these directors also
received, on  February 8, 2000, warrants  to  purchase 10,000,000
shares of common stock at $0.10  per share, expiring in 10 years.

Item 3.  Defaults Upon Senior Securities.

     None

Item 4.  Submission of Matters to a Vote of Security Holders.

At  the annual meeting of stockholders held on June 6, 2000,  the
following matters were submitted to stockholders' vote  and  were
approved  by  a  majority  of votes:  (1)  seven  directors  were
elected:   Joseph C. Abeles, John A. Cenerazzo, Stephen  F.  Hiu,
Thomas  L.  Kempner, Michael G. Kimelman, Sidney R.  Knafel,  and
Patrick  F.  Monahan;  and (2) approval  of  the  appointment  of
Berenson & Company LLP as the Company's independent auditors  for
2000.

                              -21-

            IGENE Biotechnology, Inc. and Subsidiary
                             PART II
                        OTHER INFORMATION


Item 4.  Submission of Matters to a Vote of Security Holders
	   continued)

<TABLE>

Results of the voting were as follows:

<CAPTION>
                                       Votes          Votes          Votes
                                       For            Against        Abstained
                                       ------------   ------------   ------------
<S>                                    <C>            <C>            <C>
     (1)  Election of Directors

               Joseph C. Abeles          43,678,272         57,090            ---
               John A. Cenerazzo         43,678,272         57,090            ---
               Stephen F. Hiu            43,678,272         57,090            ---
               Thomas L. Kempner         43,678,272         57,090            ---
               Michael G. Kimelman       43,678,272         57,090            ---
               Sidney R. Knafel          43,678,272         57,090            ---
               Patrick F. Monahan        43,678,272         57,090            ---

     (2)  Approval of Auditors           43,554,308        114,764         66,290
</TABLE>

Item 5.  Other Information

     None

Item 6.  Exhibits and Reports on Form 8-K

     (a)  Exhibits

          27.  Financial Data Schedule

     (b)  Reports on Form 8K - None



                              -22-

                           SIGNATURES

     In accordance with the requirements of the Exchange Act, the
     registrant caused this report to be signed on its behalf by
     the undersigned, thereunto duly authorized.



                                  IGENE Biotechnology, Inc.
                                  ________________________________

                                  (Registrant)



     Date August 14, 2000    By   /s/Stephen F. Hiu
                                  Stephen F. Hiu
                                  President and Treasurer
                                  (On behalf of the Registrant and as
                                  Principal Financial Officer)

                              -23-